Board tracked Radar started tracking this company’s job board (14 open jobs at last check). source ↗
Trial start Phase 1/Phase 2: REC-7735 in Participants With Solid Tumors source ↗
Trial start Phase 1/Phase 2: A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer source ↗
Trial start Phase 2: The Clostridioides Difficile Trial of REC-3964 source ↗
Trial start Phase 2: A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation source ↗
Trial start Phase 1/Phase 2: Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) source ↗
Trial start Phase 2/Phase 3: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas source ↗
Trial start Phase 2: The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 source ↗
Upcoming milestones
2027-06 (ESTIMATED) · Phase 1/Phase 2 · Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) · NCT05552755
Oct 30, 2028 (ESTIMATED) · Phase 1/Phase 2 · A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer · NCT06678659
2031-01 (ESTIMATED) · Phase 1/Phase 2 · REC-7735 in Participants With Solid Tumors · NCT07819136
Estimated primary completion per ClinicalTrials.gov. Dates move.
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
NIH award 5R44AG053131-04 FY2020: $447,905 awarded for that fiscal year; activity R44 (SBIR); PI GIBSON, CHRISTOPHER; recipient as written: RECURSION PHARMACEUTICALS, LLC, SALT LAKE CITY, UT. Novel Methodology for Id source ↗
NIH award 5R44AG053131-03 FY2019: $434,004 awarded for that fiscal year; activity R44 (SBIR); PI GIBSON, CHRISTOPHER; recipient as written: RECURSION PHARMACEUTICALS, LLC, SALT LAKE CITY, UT. Novel Methodology for Id source ↗
NIH award 4R44AG053131-02 FY2018: $509,173 awarded for that fiscal year; activity R44 (SBIR); PI GIBSON, CHRISTOPHER; recipient as written: RECURSION PHARMACEUTICALS, LLC, SALT LAKE CITY, UT. Novel Methodology for Id source ↗
NIH award 1R44AG053131-01 FY2016: $223,006 awarded for that fiscal year; activity R44 (SBIR); PI GIBSON, CHRISTOPHER; recipient as written: RECURSION PHARMACEUTICALS, LLC, SALT LAKE CITY, UT. Novel Methodology for Id source ↗
NIH award 5R44TR001197-02 FY2016: $650,041 awarded for that fiscal year; activity R44 (SBIR); PI GIBSON, CHRISTOPHER; recipient as written: RECURSION PHARMACEUTICALS, LLC, SALT LAKE CITY, UT. Expansion of an efficien source ↗
NIH award 1R43HD084025-01A1 FY2015: $224,625 awarded for that fiscal year; activity R43 (SBIR); PI GIBSON, CHRISTOPHER; recipient as written: RECURSION PHARMACEUTICALS, LLC, SALT LAKE CITY, UT. Application of an effi source ↗
NIH award 1R43HL127820-01 FY2015: $217,352 awarded for that fiscal year; activity R43 (SBIR); PI GIBSON, CHRISTOPHER; recipient as written: RECURSION PHARMACEUTICALS, LLC, SALT LAKE CITY, UT. HLS13-04 High-Content Hi source ↗
NIH award 1R44TR001197-01 FY2015: $809,130 awarded for that fiscal year; activity R44 (SBIR); PI GIBSON, CHRISTOPHER; recipient as written: RECURSION PHARMACEUTICALS, LLC, SALT LAKE CITY, UT. Expansion of an efficien source ↗
Raises and investors new
Form D raises come from the company’s own SEC filing (last 2 years).
InvestorListed in the portfolio of Lux Capital (captured Oct 12, 2026). portfolio page ↗
